Iolia Akaev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Iolia Akaev has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Siavash Rahimi
Istituto Dermopatico dell’Immacolata, IDI-IRCCS, 00167 Rome, Italy
9 shared publications Chit Cheng Yeoh
7 shared publicationsPeter A. Brennan
Department of Oral and Maxillofacial Surgery, Queen Alexandra Hospital, Portsmouth, UK
5 shared publicationsCarla Marani
Histopathology Division, San Carlo di Nancy Hospital, Rome, Italy
3 shared publicationsMridula Chopra
University of Portsmouth
3 shared publicationsAnzhela Krol
2 shared publications
Latest Publications
- Open Access
- 19 March 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 547
Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom
The aim of this audit was to evaluate the usefulness and serviceability of testing for pathogenic mutations in BRCA1 or BRCA2 (BRCA1/2) genes in ovarian cancer (OC) patients. One hundred and thirty-five patients with more common histological sub-types of OC were retrospectively identified between 2011 and 2019. The fail rate of the molecular analysis was 7.4% (10/135). One hundred and twenty-five records were evaluated: 99 (79.2%) patients had wild-type BRCA (both somatic and germline); tumour BRCA1/2 (tBRCA1/2) pathogenic mutations were found in 20 (16%) patients with distribution between BRCA1 and BRCA2 being 40% and 60%, respectively; 13 (10.4%) patients with pathogenic variants had germline mutations; and tBRCA1/2 with variant of unknown significance (VUS), in the absence of pathogenic BRCA1 or BRCA2 variants, was detected in 6 (4.8%) patients. Our data show that expanding the molecular service to the routine first-tumour testing for patients with OC will potentially increase the detection rate of BRCA mutations, thereby providing early benefits of PARP inhibitors therapy. The tumour testing service should continue to be offered to newly diagnosed patients with high-grade epithelial cancers, including high-grade serous carcinoma, but also with carcinosarcomas and poorly-differentiated metastatic adenocarcinomas of unknown origin.
- 19 March 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 547
Open AccessTumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom
The aim of this audit was to evaluate the usefulness and serviceability of testing for pathogenic mutations in BRCA1 or BRCA2 (BRCA1/2) genes in ovarian cancer (OC) patients. One hundred and thirty-five patients with more common histological sub-types of OC were retrospectively identified between 2011 and 2019. The fail rate of the molecular analysis was 7.4% (10/135). One hundred and twenty-five records were evaluated: 99 (79.2%) patients had wild-type BRCA (both somatic and germline); tumour BRCA1/2 (tBRCA1/2) pathogenic mutations were found in 20 (16%) patients with distribution between BRCA1 and BRCA2 being 40% and 60%, respectively; 13 (10.4%) patients with pathogenic variants had germline mutations; and tBRCA1/2 with variant of unknown significance (VUS), in the absence of pathogenic BRCA1 or BRCA2 variants, was detected in 6 (4.8%) patients. Our data show that expanding the molecular service to the routine first-tumour testing for patients with OC will potentially increase the detection rate of BRCA mutations, thereby providing early benefits of PARP inhibitors therapy. The tumour testing service should continue to be offered to newly diagnosed patients with high-grade epithelial cancers, including high-grade serous carcinoma, but also with carcinosarcomas and poorly-differentiated metastatic adenocarcinomas of unknown origin.
- Open Access
- 3 March 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 429
Update on Endometrial Stromal Tumours of the Uterus
Endometrial stromal tumours (ESTs) are rare, intriguing uterine mesenchymal neoplasms with variegated histopathological, immunohistochemical and molecular characteristics. Morphologically, ESTs resemble endometrial stromal cells in the proliferative phase of the menstrual cycle. In 1966 Norris and Taylor classified ESTs into benign and malignant categories according to the mitotic count. In the most recent classification by the WHO (2020), ESTs have been divided into four categories: Endometrial Stromal Nodules (ESNs), Low-Grade Endometrial Stromal Sarcomas (LG-ESSs), High-Grade Endometrial Stromal Sarcomas (HG-ESSs) and Undifferentiated Uterine Sarcomas (UUSs). ESNs are clinically benign. LG-ESSs are tumours of low malignant potential, often with indolent clinical behaviour, with some cases presented with a late recurrence after hysterectomy. HG-ESSs are tumours of high malignant potential with more aggressive clinical outcome. UUSs show high-grade morphological features with very aggressive clinical behavior. With the advent of molecular techniques, the morphological classification of ESTs can be integrated with molecular findings in enhanced classification of these tumours. In the future, the morphological and immunohistochemical features correlated with molecular categorisation of ESTs, will become a robust means to plan therapeutic decisions, especially in recurrences and metastatic disease. In this review, we summarise the morphological, immunohistochemical and molecular features of ESTs with particular reference to the most recent molecular findings.
- 3 March 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 429
Open AccessUpdate on Endometrial Stromal Tumours of the Uterus
Endometrial stromal tumours (ESTs) are rare, intriguing uterine mesenchymal neoplasms with variegated histopathological, immunohistochemical and molecular characteristics. Morphologically, ESTs resemble endometrial stromal cells in the proliferative phase of the menstrual cycle. In 1966 Norris and Taylor classified ESTs into benign and malignant categories according to the mitotic count. In the most recent classification by the WHO (2020), ESTs have been divided into four categories: Endometrial Stromal Nodules (ESNs), Low-Grade Endometrial Stromal Sarcomas (LG-ESSs), High-Grade Endometrial Stromal Sarcomas (HG-ESSs) and Undifferentiated Uterine Sarcomas (UUSs). ESNs are clinically benign. LG-ESSs are tumours of low malignant potential, often with indolent clinical behaviour, with some cases presented with a late recurrence after hysterectomy. HG-ESSs are tumours of high malignant potential with more aggressive clinical outcome. UUSs show high-grade morphological features with very aggressive clinical behavior. With the advent of molecular techniques, the morphological classification of ESTs can be integrated with molecular findings in enhanced classification of these tumours. In the future, the morphological and immunohistochemical features correlated with molecular categorisation of ESTs, will become a robust means to plan therapeutic decisions, especially in recurrences and metastatic disease. In this review, we summarise the morphological, immunohistochemical and molecular features of ESTs with particular reference to the most recent molecular findings.
- Open Access
- 17 December 2019
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 26 (4) , 1965-1980
Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis Ex Vivo
The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate tumours, in which the enzyme is markedly overexpressed. Overexpression, coupled with highly selective specificity for cleavage of substrates at the C-terminus of asparagine (Asn) residues, make legumain an attractive biochemical target for potential diagnosis, prognosis and treatment. We report the design, synthesis, characterisation and preliminary evaluation of a new rhodamine-B (Rho-B)-labelled legumain peptide substrate probe5[Rho-Pro-Ala-Asn-PEG-AQ(4-OH)] and its selective targeting to lysosomes in PC3 prostate cancer cells. Probe5was efficiently activated by recombinant human legumain to afford the high quantum yield reporter fluorophore tripeptide4b(Rho-Pro-Ala-Asn-OH) with concomitant release of intense fluorescence. Furthermore, probe5was activated upon incubation with homogenates derived from fresh-frozen tissue material of prostatectomy specimens. Probe5represents a new viable biochemical tool for probing the activity of legumain with the potential to be used in ex vivo diagnostics in the cancer pathology laboratory.
- 17 December 2019
- Published by Springer Nature in International Journal of Peptide Research and Therapeutics
- Vol. 26 (4) , 1965-1980
Open AccessDesign of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis Ex Vivo
The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate tumours, in which the enzyme is markedly overexpressed. Overexpression, coupled with highly selective specificity for cleavage of substrates at the C-terminus of asparagine (Asn) residues, make legumain an attractive biochemical target for potential diagnosis, prognosis and treatment. We report the design, synthesis, characterisation and preliminary evaluation of a new rhodamine-B (Rho-B)-labelled legumain peptide substrate probe5[Rho-Pro-Ala-Asn-PEG-AQ(4-OH)] and its selective targeting to lysosomes in PC3 prostate cancer cells. Probe5was efficiently activated by recombinant human legumain to afford the high quantum yield reporter fluorophore tripeptide4b(Rho-Pro-Ala-Asn-OH) with concomitant release of intense fluorescence. Furthermore, probe5was activated upon incubation with homogenates derived from fresh-frozen tissue material of prostatectomy specimens. Probe5represents a new viable biochemical tool for probing the activity of legumain with the potential to be used in ex vivo diagnostics in the cancer pathology laboratory.
- 12 September 2019
- Published by Morressier GmbH
Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in Ovarian Cancer patients eligible for PARP inhibitors therapy.
Objectives The aim of the study was to investigate the rate of concordance of germline BRCA1/2 (gBRCA1/2) with somatic BRCA1/2 (sBRCA1/2) pathogenic mutations to increase screening uptake for prescription of the newly NICE approved PARP inhibitor tablets available for gBRCA and sBRCA mutation carriers. Methods 70 patients diagnosed with ovarian cancer were screened: 50
- 12 September 2019
- Published by Morressier GmbH
Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in Ovarian Cancer patients eligible for PARP inhibitors therapy.
Objectives The aim of the study was to investigate the rate of concordance of germline BRCA1/2 (gBRCA1/2) with somatic BRCA1/2 (sBRCA1/2) pathogenic mutations to increase screening uptake for prescription of the newly NICE approved PARP inhibitor tablets available for gBRCA and sBRCA mutation carriers. Methods 70 patients diagnosed with ovarian cancer were screened: 50
- 29 August 2019
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 49 (2) , 110-116
A proposal for classification of oropharyngeal squamous cell carcinoma: Morphology and status of HPV by immunohistochemistry and molecular biology
The current three‐tier grading system (well, moderate and poorly differentiated) used to morphologically classify head and neck squamous cell carcinoma (HNSCC) is inadequate for categorisation of oropharyngeal squamous cell carcinoma (OPSCC) owing to the lack of prognostic value. The aim of this study was to assess the validity of a classification system for OPSCC based on morphology and human papilloma virus (HPV) infection status. Haematoxylin and eosin slides of 121 patients (100 M, 21 F, age range 40‐89 years) with OPSCC were reviewed and categorised as histological types I, II and III. The presence of HPV was assessed by immunohistochemistry with p16 and RNAscope In situ hybridization (ISH). The follow‐up period was 36 months. Ninety‐six patients were p16+ and clinical stage I. Patient survival with types I, II and III was 93%, 50% and 96%, respectively. Twenty‐five patients were p16−: 10 clinical stage I and 15 stage III. Amongst this group, no type I morphology was identified. At follow‐up, 65% of type II and 75% of type III patients were alive. All p16+ cases were also positive for E6/E7 mRNA high‐risk HPV by ISH, while 23 p16− cases were negative and two were positive. Cox regression identified three predictors of mortality: older age (HR = 1.14, 95% CI = 1.06‐1.23, P = .001); female gender (HR = 0.22.95% CI 0.05‐0.88, P = .033); and type II morphology (HR = 13.1, 95% CI = 1.09‐157.0, P = .043). OPSCC morphological classification in three sub‐types, along with HPV infection status, seems to reflect the outcome of patients with OPSCC.
- 29 August 2019
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 49 (2) , 110-116
A proposal for classification of oropharyngeal squamous cell carcinoma: Morphology and status of HPV by immunohistochemistry and molecular biology
The current three‐tier grading system (well, moderate and poorly differentiated) used to morphologically classify head and neck squamous cell carcinoma (HNSCC) is inadequate for categorisation of oropharyngeal squamous cell carcinoma (OPSCC) owing to the lack of prognostic value. The aim of this study was to assess the validity of a classification system for OPSCC based on morphology and human papilloma virus (HPV) infection status. Haematoxylin and eosin slides of 121 patients (100 M, 21 F, age range 40‐89 years) with OPSCC were reviewed and categorised as histological types I, II and III. The presence of HPV was assessed by immunohistochemistry with p16 and RNAscope In situ hybridization (ISH). The follow‐up period was 36 months. Ninety‐six patients were p16+ and clinical stage I. Patient survival with types I, II and III was 93%, 50% and 96%, respectively. Twenty‐five patients were p16−: 10 clinical stage I and 15 stage III. Amongst this group, no type I morphology was identified. At follow‐up, 65% of type II and 75% of type III patients were alive. All p16+ cases were also positive for E6/E7 mRNA high‐risk HPV by ISH, while 23 p16− cases were negative and two were positive. Cox regression identified three predictors of mortality: older age (HR = 1.14, 95% CI = 1.06‐1.23, P = .001); female gender (HR = 0.22.95% CI 0.05‐0.88, P = .033); and type II morphology (HR = 13.1, 95% CI = 1.09‐157.0, P = .043). OPSCC morphological classification in three sub‐types, along with HPV infection status, seems to reflect the outcome of patients with OPSCC.
- Open Access
- 1 July 2019
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 27 (6) , 466-470
Immunohistochemical Expression of Different Subtypes of Cytokeratins by Endometrial Stromal Sarcoma
Endometrial stromal sarcomas (ESS) are rare and understudied gynecologic mesenchymal neoplasms. These tumors can be confused with many other gynecologic and nongynecologic tumors due to their variegated morphologic appearance and nonspecific immunohistochemical profile. ESS can express cytokeratin (CK) and, therefore, may be misdiagnosed as carcinoma especially in extrauterine locations and when recurrence/metastasis is present. In this study, we investigated the expression of a wide spectrum of CKs consisting of AE1/3, CAM 5.2, HMCK, MNF116, CK5, CK6, CK7, CK8/18, CK14, CK17, CK19, and CK20 in 6 low-grade and 5 high-grade ESS. In addition, staining for estrogen receptor, progesterone receptor, CD10, and cyclin D1 was performed. Our results showed that CKs AE1/3, CAM 5.2, MNF116, and CK8/18 are more expressed in low-grade ESS, whereas high-grade ESS express more AE1/3 and CAM 5.2. In problematic cases, especially in recurrences or metastases, the immunohistochemical panel of antibodies AE1/3, MNF116, CAM 5.2, and CK8/18, together with other classic immunohistochemical markers CD10, cyclin D1, estrogen receptor, and progesterone receptor, may be helpful in the differential diagnosis between ESS and other gynecologic and nongynecologic malignancies.
- 1 July 2019
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 27 (6) , 466-470
Open AccessImmunohistochemical Expression of Different Subtypes of Cytokeratins by Endometrial Stromal Sarcoma
Endometrial stromal sarcomas (ESS) are rare and understudied gynecologic mesenchymal neoplasms. These tumors can be confused with many other gynecologic and nongynecologic tumors due to their variegated morphologic appearance and nonspecific immunohistochemical profile. ESS can express cytokeratin (CK) and, therefore, may be misdiagnosed as carcinoma especially in extrauterine locations and when recurrence/metastasis is present. In this study, we investigated the expression of a wide spectrum of CKs consisting of AE1/3, CAM 5.2, HMCK, MNF116, CK5, CK6, CK7, CK8/18, CK14, CK17, CK19, and CK20 in 6 low-grade and 5 high-grade ESS. In addition, staining for estrogen receptor, progesterone receptor, CD10, and cyclin D1 was performed. Our results showed that CKs AE1/3, CAM 5.2, MNF116, and CK8/18 are more expressed in low-grade ESS, whereas high-grade ESS express more AE1/3 and CAM 5.2. In problematic cases, especially in recurrences or metastases, the immunohistochemical panel of antibodies AE1/3, MNF116, CAM 5.2, and CK8/18, together with other classic immunohistochemical markers CD10, cyclin D1, estrogen receptor, and progesterone receptor, may be helpful in the differential diagnosis between ESS and other gynecologic and nongynecologic malignancies.
- 4 June 2018
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 47 (7) , 691-695
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target
The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.
- 4 June 2018
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 47 (7) , 691-695
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target
The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non‐squamous cell head and neck cancers (NSCC‐HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti‐androgen agents and drugs administered orally, more targetable AR‐driven NSCC‐HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.
- 1 March 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44, S42
An evaluation of the microvessel density (MVD) as a prognostic biomarker in adenocarcinoma of prostate
- 1 March 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44, S42
An evaluation of the microvessel density (MVD) as a prognostic biomarker in adenocarcinoma of prostate
- 10 February 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (5) , TPS119
Oral cavity squamous cell carcinoma and Waldeyer ring squamous cell carcinoma PDL-1 expression: A large, retrospective, single institution site series on head and neck squamous cell carcinoma, looking at the relationship with morphology, human papilloma virus and p16.
TPS119 Background: The most frequent type of epithelial malignancy in oral cavity and Waldeyer's ring (WR) is squamous cell carcinoma (SCC). Patients with Head and Neck SCC (HNSCC) show reduced levels of CD3+, CD4+, and CD8+ T cells compare to healthy controls. SCCs with a higher number of intra-tumoural CD4+ and CD8+ lymphocytes are associated with better prognosis. Programmed death receptor ligand (PD-L1 ) is present on the surface of neoplastic cells in SCC. T cells harbour inhibitory receptors (the so-called immune checkpoints) such as PD-1. Activation of this immune checkpoints results in T cell deactivation. The PD-1/PDL-1 interaction provokes an immunosuppressive effect which allows the tumour to evade immune destruction. However, WR SCCs present some diversities comparing to oral cavity SCC: younger age, frequent neck LN metastasis, often cystic, distinct morphology: often undifferentiated and solid (nonkeratinizing basal cell morphology), better prognosis, often HPV+, often p16+, an increased number of CD56+ cytotoxic NK. Methods: We have a series of 90 cases of epithelial malignancy in oral cavity and Waldeyer's ring (WR)Squamous cell Carcinoma, registered for Ethics IRAS number for Translational study with Immunohistochemistry; Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR); Fluorescence in Situ Hybridisation (FISH); Next Generation Sequencing; Digital Imaging scanning and visualising microscopy. The Study will show the relationship of PDL-1 expression with morphology, Human Papilloma Virus (HPV) infection and p16 expression, answering if the oral cavity SCC and Waldeyer's Ring SCC express PD-L1 in the same way.
- 10 February 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (5) , TPS119
Oral cavity squamous cell carcinoma and Waldeyer ring squamous cell carcinoma PDL-1 expression: A large, retrospective, single institution site series on head and neck squamous cell carcinoma, looking at the relationship with morphology, human papilloma virus and p16.
TPS119 Background: The most frequent type of epithelial malignancy in oral cavity and Waldeyer's ring (WR) is squamous cell carcinoma (SCC). Patients with Head and Neck SCC (HNSCC) show reduced levels of CD3+, CD4+, and CD8+ T cells compare to healthy controls. SCCs with a higher number of intra-tumoural CD4+ and CD8+ lymphocytes are associated with better prognosis. Programmed death receptor ligand (PD-L1 ) is present on the surface of neoplastic cells in SCC. T cells harbour inhibitory receptors (the so-called immune checkpoints) such as PD-1. Activation of this immune checkpoints results in T cell deactivation. The PD-1/PDL-1 interaction provokes an immunosuppressive effect which allows the tumour to evade immune destruction. However, WR SCCs present some diversities comparing to oral cavity SCC: younger age, frequent neck LN metastasis, often cystic, distinct morphology: often undifferentiated and solid (nonkeratinizing basal cell morphology), better prognosis, often HPV+, often p16+, an increased number of CD56+ cytotoxic NK. Methods: We have a series of 90 cases of epithelial malignancy in oral cavity and Waldeyer's ring (WR)Squamous cell Carcinoma, registered for Ethics IRAS number for Translational study with Immunohistochemistry; Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR); Fluorescence in Situ Hybridisation (FISH); Next Generation Sequencing; Digital Imaging scanning and visualising microscopy. The Study will show the relationship of PDL-1 expression with morphology, Human Papilloma Virus (HPV) infection and p16 expression, answering if the oral cavity SCC and Waldeyer's Ring SCC express PD-L1 in the same way.